Michael Chuong: MRIdian Linac utilization experience across the first 6 years of practice
Michael Chuong, GI Section Editor for the International Journal of Radiation Oncology Biology Physics, shared an article on LinkedIn:
“Congrats to the MR-guided RT team at Baptist Health Miami Cancer Institute for publishing our MRIdian Linac utilization experience across the first 6 years of practice! We became one of the first MR-Linac programs in the world in 2018.
We most commonly utilize the MRIdian Linac to treat complex and unresectable tumors in the abdomen and pelvis with ablative doses that are dramatically higher than can otherwise be safely given with other advanced radiation devices. Our practice largely consists of pancreatic and oligometastatic cancers. Ablative MR-guided RT achieves an extremely high rate of local control even for the most challenging tumors and this can improve long-term patient survival.
This is typically done in 5 or fewer fractions and increasingly just 1. No anesthesia, completely non-invasive, each treatment is typically completed in 40-50 minutes, and there is no patient downtime after.
I am immensely grateful to be one part of an incredibly skilled team that is not afraid to think outside of the box! We have several innovative ongoing and future clinical trials that aim to impact the standard of care.”
Authors: Robert A. Herrera et al.
Michael Chuong is the GI Section Editor for the International Journal of Radiation Oncology Biology Physics. He is a Professor at Florida International University’s Herbert Wertheim College of Medicine and serves as the Vice Chair and Medical Director of the Department of Radiation Oncology at the Miami Cancer Institute. Additionally, he is the Chief of the GI Radiation Oncology Service at Baptist Health South Florida, specializing in the treatment of gastrointestinal cancers.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023